Skip to main content

Table 1 Methodological quality summary: review authors' judgments about each methodological quality item for each included study.

From: Systematic review and meta-analysis on the adverse events of rimonabant treatment: Considerations for its potential use in hepatology

Author (year) Subjects included Duration
(months)
Primary outcome Adequate sequence generation Allocation concealment Blinding Incomplete outcome data Selective outcome reporting
Van Gaal (2005)* placebo = 305 12 Weight change Yes Yes Yes No No
  rimonabant 5 mg = 603        
  rimonabant 20 mg = 599        
Després (2005)* placebo = 342 12 Weight change Yes Yes Yes No No
  rimonabant 5 mg = 345        
  rimonabant 20 mg = 346        
Pi-Sunyer (2006)* placebo = 607 12 Weight change Yes Yes Yes No No
  rimonabant 5 mg = 1214        
  rimonabant 20 mg = 1219        
Scheen (2006)* placebo = 348 12 Weight change Yes Yes Yes No No
  rimonabant 5 mg = 358        
  rimonabant 20 mg = 339        
Nissen (2008) placebo = 417 18 Change in percent atheroma volume Yes Yes Yes No No
  rimonabant 20 mg = 422        
Van Gaal (2008)* placebo = 168 24 Weight change Yes Yes Yes No No
  rimonabant 5 mg = 363        
  rimonabant 20 mg = 305        
Soyka (2008) placebo = 127 3 Time to first drink Yes Yes Yes No No
  rimonabant 20 mg = 131   Time to relapse to first heavy drinking      
Rosenstock (2008) Placebo = 140 6 HbA1c NR NR Yes No No
  Rimonabant 20 mg = 138        
Després (2009) Placebo = 395 12 Change in HDL cholesterol and triglycerides Yes Yes Yes No No
  Rimonabant 20 mg = 404        
  1. * The articles with asterisk are part of Rimonabant In Obesity (RIO) trials